Recent News

• 06.02.2025 - BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
• 05.20.2025 - Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
• 05.20.2025 - Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
• 05.20.2025 - Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
• 05.19.2025 - Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
• 05.19.2025 - Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
• 05.19.2025 - Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
• 05.14.2025 - BofA Securities 2025 Health Care Conference
• 05.14.2025 - BofA Securities 2025 Health Care Conference
• 05.14.2025 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 05.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 144 Report of proposed sale of securities
• 05.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership